Scholarlink

Background <p>The use of immune checkpoint inhibitors may cause neurological immune-related adverse events in patients. Here, we report a case of autonomic nervous system involvement in nivolumab-induced autoimmune encephalitis with dysautonomia.</p> Case presentation <p>A 78-year-old man presented with a 4-month history of orthostatic hypotension, dysgeusia, and dysosmia following a 2-month course of nivolumab prescribed for malignant mesothelioma. Serum was positive for anti-neuronal nuclear antibody type 1. Diagnostic work-up, including imaging, neurological, and biochemical tests, suggested the diagnosis of nivolumab-induced autoimmune encephalitis with pronounced autonomic nervous system involvement. On day 10 of hospitalization, the patient received high-dose intravenous methylprednisolone followed by oral prednisone. The patient was discharged on day 29 with continued administration of corticosteroids and midodrine. At the 1-month outpatient follow-up, the patient remained stable and reported independent ambulation without marked orthostatic symptoms.</p> Conclusions <p>We discuss a possible mechanism of dysautonomia in this case and draw attention to newly emerging autonomic symptoms and olfactory impairments during therapy with immune checkpoint inhibitors.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Dysautonomia and dysosmia associated with anti-Hu antibodies induced by immune checkpoint inhibitors: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月22日

查看全文
  • Masataka Fujimoto,
  • Kota Igari,
  • Motoki Fujimaki,
  • Shinji Saiki

摘要

Background

The use of immune checkpoint inhibitors may cause neurological immune-related adverse events in patients. Here, we report a case of autonomic nervous system involvement in nivolumab-induced autoimmune encephalitis with dysautonomia.

Case presentation

A 78-year-old man presented with a 4-month history of orthostatic hypotension, dysgeusia, and dysosmia following a 2-month course of nivolumab prescribed for malignant mesothelioma. Serum was positive for anti-neuronal nuclear antibody type 1. Diagnostic work-up, including imaging, neurological, and biochemical tests, suggested the diagnosis of nivolumab-induced autoimmune encephalitis with pronounced autonomic nervous system involvement. On day 10 of hospitalization, the patient received high-dose intravenous methylprednisolone followed by oral prednisone. The patient was discharged on day 29 with continued administration of corticosteroids and midodrine. At the 1-month outpatient follow-up, the patient remained stable and reported independent ambulation without marked orthostatic symptoms.

Conclusions

We discuss a possible mechanism of dysautonomia in this case and draw attention to newly emerging autonomic symptoms and olfactory impairments during therapy with immune checkpoint inhibitors.